Zami Aberman
Net Worth

Last updated:

What is Zami Aberman net worth?

The estimated net worth of Mr. Zami Aberman is at least $20,211,429 as of 8 Apr 2019. He owns shares worth $71,429 as insider and has received compensation worth at least $20,140,000 in Pluristem Therapeutics Inc..

What is the salary of Zami Aberman?

Mr. Zami Aberman salary is $1,060,000 per year as Executive Chairman in Pluristem Therapeutics Inc..

How old is Zami Aberman?

Mr. Zami Aberman is 71 years old, born in 1954.

What stocks does Zami Aberman currently own?

As insider, Mr. Zami Aberman owns shares in one company:

Company Title Shares Price per share Total value
Pluristem Therapeutics Inc. (PSTI) Executive Chairman 71,429 $1 $71,429

What does Pluristem Therapeutics Inc. do?

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

PSTI logo
PSTI
Pluristem Therapeutics Inc.
$1

Zami Aberman insider trading

Pluristem Therapeutics Inc.

Mr. Zami Aberman has made 7 insider trades between 2006-2019, according to the Form 4 filled with the SEC. Most recently he purchased 71,429 units of PSTI stock on 8 Apr 2019.

The largest trade he's ever made was exercising 71,429 units of PSTI stock on 8 Apr 2019. As of 8 Apr 2019 he still owns at least 71,429 units of PSTI stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock Warrant 71,429 N/A N/A
Purchase
Common Stock 71,429 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 15,000 N/A N/A
Purchase
Common Stock 31,000 N/A N/A
Purchase
Common Stock 9,900 N/A N/A
Purchase
Common Stock 25,500 N/A N/A
Purchase
Common Stock 25,000 N/A N/A
Purchase
Common Stock 13,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 30,000 N/A N/A
Sale
Common Stock 67,850 N/A N/A
Sale
Common Stock 2,000 N/A N/A
Sale
Common Stock 150 N/A N/A
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 33,853 N/A N/A
Sale
Common Stock 25,000 N/A N/A
Sale
Common Stock 25,000 N/A N/A
Purchase
common shares 3,000 N/A N/A

Pluristem Therapeutics key executives

Pluristem Therapeutics Inc. executives and other stock owners filed with the SEC: